Emergent Biosolutions, Inc. (EBS)

NYSE: EBS · Pharmaceutical Preparations · Gaithersburg, MD · filing with the SEC since 2006

Grade4.6

◀ Past 4.6● Present 5.4▶ Future 3.5

Overview Business Financials Grade Forecast Sentiment Ownership People Filings Patents Chart

Income statement, as filed

In thousands of US dollars (USD), as filed; per-share figures in US dollars; share counts in millions. The fiscal year ends in December.

Income statement, by fiscal year, newest first
Fiscal year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017	FY 2016
Period ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017	Dec 31, 2016
Report filed	Feb 27, 2026	Mar 4, 2025	Mar 8, 2024	Mar 1, 2023	Feb 25, 2022	Feb 19, 2021	Feb 25, 2020	Feb 22, 2019	Feb 23, 2018	Feb 28, 2017
Revenue	742,900	1,043,600	1,049,300	1,117,500^r	1,773,600^r	1,555,400	1,106,000	782,400	560,900	488,800
Cost of revenue	326,200	681,300	705,400	693,100^r	748,100^r	537,000^r	433,500	322,300	187,700	126,300
Gross profit	·	·	317,600	383,000^r	891,300^r	925,200^r	·	·	·	·
Research and development	53,200	70,700	111,400	188,300^r	235,200^r	237,900^r	226,200	142,800	97,400^r	106,900^r
Selling, general and administrative	186,100	308,000	368,400	339,500^r	348,700^r	304,100^r	273,500	202,500	142,900^r	143,100^r
Total operating expenses	·	·	·	·	·	·	991,900	692,600	436,600	383,300
Total costs and expenses	642,800	1,152,300	1,775,700	1,287,500^r	1,432,200^r	1,138,800^r	991,900	692,600	·	·
Operating income	100,100	-108,700	-726,400	-170,000^r	341,400^r	438,500^r	114,100	89,800	124,300^r	105,500^r
Interest expense	59,300	71,000	87,900	37,300	34,500	31,300	38,400	9,900	6,600^r	7,600^r
Interest and investment income	·	·	·	·	·	·	·	·	1,753	1,053
Other income (expense), net	54,200	11,900^r	6,400^r	-11,700	-3,700	4,700	1,700	1,600	900^r	1,300^r
Total non-operating income (expense)	-17,300	-34,200	-4,800	-49,000	-38,200	-26,600	-36,700	-8,300	-5,700^r	-6,300^r
Income before income taxes	82,800	-142,900	-731,200	-219,000^r	303,200^r	411,900^r	77,400	81,500	118,600^r	99,200^r
Income tax expense	30,200	47,700	29,300	-7,400^r	83,700^r	106,100^r	22,900	18,800	36,000^r	36,700^r
Income from continuing operations	·	·	·	·	·	·	·	62,700	82,600^r	62,500^r
Income from discontinued operations	·	·	·	·	·	·	·	0	0	-10,700^r
Net income including non-controlling interests	·	·	·	·	·	·	·	62,700	82,600	51,800^r
Net income	52,600	-190,600	-760,500	-211,600^r	219,500^r	305,800^r	54,500	62,700	82,600^r	51,800^r
Earnings per share, basic	0.98	-3.60	-14.85	-4.22^r	4.10^r	5.80^r	1.06	1.25	1.98	1.29
Earnings per share, diluted	0.93	-3.60	-14.85	-4.22^r	4.06^r	5.68^r	1.04	1.22	1.71	1.13
Weighted average shares, basic	53.5	53.0	51.2	50.1	53.5	52.7	51.5	50.1	41.8^r	40.2^r
Weighted average shares, diluted	56.7	53.0	51.2	50.1	54.1	53.8	52.4	51.4	50.3^r	49.3^r

As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. ^r restated by the company in a later report; ^b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.

What each line is, and the XBRL concept behind it

Revenue what customers paid for what it sold

us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues

Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfGoodsAndServicesSold

Gross profit revenue less the cost of what it soldus-gaap:GrossProfit

Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpense

Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense

Total operating expenses the running costs togetherus-gaap:OperatingExpenses

Total costs and expenses every operating cost, the cost of revenue includedus-gaap:OperatingCostsAndExpenses

Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss

Interest expense what its borrowing cost

us-gaap:InterestExpenseNonoperating
us-gaap:InterestExpense

Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest

Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense

Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense

Income before income taxes profit before tax

us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments

Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit

Income from continuing operations profit from the businesses it keepsus-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest

Income from discontinued operations profit or loss from businesses it sold or closedus-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax

Net income including non-controlling interests the whole group's profit, minority holders' share includedus-gaap:ProfitLoss

Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss

Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic

Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted

Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic

Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

SI Assistanton EBS · research, not advice